Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

How Apple Inc. (AAPL) ResearchKit Revolutionizes Medical Research: Ron Winslow

Apple Inc. (NASDAQ:AAPL) ResearchKit is leading to medical research getting more participation from volunteers which could mean breakthroughs in the fight to find cures to different diseases.

Ron Winslow also adds in an interview on The Wall Street Journal’s Lunch Break with Tanya Rivero that it is not only researchers who are finding great benefits from the new research platform Apple Inc. (NASDAQ:AAPL), patients are also liking the capabilities of the new platform.

“For all five [of these early apps powered by ResearchKit], the total is about 60,000 as of now which is a remarkable amount. One researcher I talked to in a breast cancer trial just spent with her colleagues three years sending out 60,000 notices to enroll 350 patients in a similar kind of trial. This kind of access that is geographically-agnostic – you can be anywhere [and] you don’t have to live next to an academic center to do this – really opens up the field for more participation,” Winslow tells Rivero.

Furthermore, the new apps for medical research have become more transparent with people about their results because of ResearchKit, Winslow, The Wall Street Journal’s deputy bureau chief for health and science, explains to Rivero.

“One of the things that they do – researchers said and a few of the patients that I talked to – they seem to hold the promise of actually giving the patients feedback on their own data. If you’re in a conventional trial, […] the data is compiled, and conclusions are reached at the end of the trial. In these trials [with ResearchKit], you’ll get the data back right away and you can actually see what your own improvement or decline might be and see if there is something that you might be able to do to make things better,” Winslow explains.

Apple, is AAPL a good stock to buy, NASDAQ:AAPL, ResearchKit, Tanya Rivero, Ron Winslow, medical research, medical trials,

Apple Inc. (NASDAQ:AAPL) announced yesterday that ResearchKit is now available to all medical researchers. The platform launched with just a limited number of partners.

Winslow points out, however, that as with anything uploaded to the Internet, there is always the risk of the data being compromised. Nonetheless, he points out that Apple Inc. (NASDAQ:AAPL) itself does not see the data which is only shared between the patient and the researchers. Furthermore, the patients control when they want to share their data, he adds.

Ken Fisher’s Fisher Asset Management owned about 10.76 million Apple Inc. (NASDAQ:AAPL) shares by the end of the last quarter of 2014.

I just made 84% in 4 daysI Just Made 84% in 4 Days By Blindly Following This Hedge Fund

I just made 84% in 4 days by blindly imitating a hedge fund’s stock pick. I will tell you how I pulled such a huge return in such a short time but let me first explain in this FREE REPORT why following hedge funds’ stock picks is one of the smartest things you can do as an investor. We launched our quarterly newsletter 2.5 years ago and not one subscriber has, since, said ‘I lost money by EXACTLY following your stock picks’. The reason is simple. You can beat index funds by creating a DREAM TEAM of hedge fund managers and investing in only their best ideas. I just made 84% in 4 days by blindly imitating one of these best ideas. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!